Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist
- 1.7k Downloads
Active surveillance (AS) is an important management option for men with low-risk, clinically localized prostate cancer. The clinical parameters for patient selection and definition of progression for AS protocols are evolving as data from several large cohorts matures. Vital to this process is the critical role pathologic parameters play in identifying appropriate candidates for AS. These findings need to be reproducible and consistently reported by surgical pathologists. This report highlights the importance of accurate pathology reporting as a critical component of these protocols.
KeywordsLocalized prostate cancer Low-risk prostate cancer Active surveillance Overtreatment Accurate pathology reporting
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR, Investigators CPSURE (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401PubMedCrossRefGoogle Scholar
- 4.Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300–4305PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131PubMedCrossRefGoogle Scholar
- 11.Network NCC (2010) NCCN clinical practice guidelines in oncology: prostate cancer. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
- 12.Dall’Era MA, Cooperberg MR, Chan JM, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112:1650–1659PubMedCrossRefGoogle Scholar
- 14.Ganz PABJ, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath K, Wessells H (2011) National institutes of health state-of-the-science conference statement: role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statement 28:1–27Google Scholar
- 15.Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, et al. (2014) The critical role of the pathologist in determining eligibility for active surveillance as a management options in patients with prostate cancer: consensus statement with recommendations supported by the college of american pathologist, international society of urologic pathologist, association of directors of anatomic and surgical pathology, the New Zealand society of pathologists and the prostate cancer foundation. Arch Pathol Lab MedGoogle Scholar
- 16.Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63:597–603PubMedCrossRefGoogle Scholar
- 19.Montironi R, Lopez-Beltran A, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L (2014) Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. Anal Quant Cytol Histol 36:61–70Google Scholar